SAR153191 (REGN88)

DRUG2 trials

Sponsors

Sanofi

Conditions

Rheumatoid Arthritis

Phase 1

Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients

CompletedNCT01328522

SanofiRheumatoid Arthritis

Start: 2011-05-31End: 2011-09-30Updated: 2011-10-24

Phase 3

Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)

CompletedNCT01146652

SanofiRheumatoid Arthritis

Start: 2010-06-21End: 2020-12-31Updated: 2022-03-28

Related Papers

Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis

Lara D. Veeken2023-02-0211 citations

Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab

Lara D. Veeken2022-11-2117 citations

Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors

Lara D. Veeken2021-04-1620 citations

Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial

ACR Open Rheumatology2020-11-0119 citations

P235 Glucocorticoid dose is progressively reduced in Patients with rheumatoid arthritis (RA) receiving sarilumab: results from the open label EXTEND study

Lara D. Veeken2020-04-01

Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment

RMD Open2019-08-0138 citations

Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes.

2018-08-0120 citations

Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis.

2017-06-0159 citations